Trial Condition(s):
Study on the safety of BAY 63-2521, how it is tolerated and the way the body absorbs, distributes and gets rid of the study drug given as a single oral dose of 1 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight
15000
Not Available
BAY 63-2521 is intended to be used for a disease that affects the blood flow through the lungs. Renal impairment is a common condition in patients with this disease. The goal of the study is to learn more about the safety of BAY 63-2521, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as a single oral dose of 1 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight
- Male and female white subjects with 18 to ≤79 years of age, BMI between 18 and 34 kg/m^2 - Women without childbearing potential or with childbearing potential but only if the pregnancy test is negative and are under highly effective contraception Inclusion criteria for subjects with renal failure: - Stable renal disease, ie. a serum creatinine value determined at least 3 - 6 months before the pre-study visit was not allowed to vary by more than 20% from the serum creatinine value determined at the pre-study visit Inclusion criteria for healthy subjects: - Mean age and body weight not allowed to vary by more than +/- 10 years and +/- 10 kg from the subjects with renal impairment, respectively Exclusion criteria for all subjects: - Febrile illness within 1 week before the start of the study - Hypersensitivity to riociguat and / or to inactive constituents - Smoking Exclusion criteria for subjects with renal failure: - Resting heart rate in the awake subject below 45 BPM or above 90 BPM - Acute renal failure or nephritis - Any organ transplant - Diastolic blood pressure (DBP) >100 mmHg and / or systolic blood pressure (SBP) >180 mmHg - Hemoglobin <8 g/dL, Proteinuria >8 g/24 hours, Serum albumin <30 g/L, Platelet count <100 x 109/L - History of bleeding within the past 3 months - Diabetes mellitus with a fasting blood glucose >220 mg/dL or HbA1c >10% - Concomitant use of any medication except medications necessary for the treatment of the kidney disease or related complications - Concomitant use of phosphodiesterase-5 inhibitors, endothelin receptor antagonists (ERAs, eg bosentan), intravenous or inhalative prostacyclins, or nitrates - Concomitant use of potent CYP3A4 inhibitors Exclusion criteria for healthy subjects: - Conspicuous findings in medical history or pre-study examination - History of relevant diseases of vital organs, central nervous system, or other organs - SBP below 100 mmHg or above 145 mmHg and / or DBP above 95 mmHg - Regular daily consumption of more than 1 liter of usual beer or the equivalent quantity of approximately 40 g of alcohol in another form
No Exclusion Criteria Available
Locations | Status | |
---|---|---|
Locations Investigative Site Kiel, Germany, 24105 | Status Completed | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Investigation of pharmacokinetics, safety, and tolerability of BAY 63-2521 in male and female subjects with renal impairment and in age- and weight- matched healthy subjects following a single oral dose of 1 mg BAY 63-2521 in a single-center, non-randomized, non-controlled, non-blinded, observational study with group stratification
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Basic Science
Allocation:
Non-randomized
Blinding:
Open Label
Assignment:
Parallel Assignment
Trial Arms:
4